BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2160446)

  • 1. Induction of minor histocompatibility antigen-specific T-helper but not T-cytotoxic response is dependent on the source of antigen-presenting cell.
    van Els CA; Bakker A; van Rood JJ; Goulmy E
    Hum Immunol; 1990 May; 28(1):39-50. PubMed ID: 2160446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
    Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
    J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
    Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
    Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Front Immunol; 2023; 14():878953. PubMed ID: 37033971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
    van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
    Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
    Mutis T; Schrama E; Melief CJ; Goulmy E
    Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
    Chen M; Shirai M; Liu Z; Arichi T; Takahashi H; Nishioka M
    J Virol; 1998 Oct; 72(10):8301-8. PubMed ID: 9733874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement of Ia-positive accessory cells in the MLR response against class II antigen on human B cell tumor line.
    Yamamoto M; Yano A
    J Immunol; 1985 Dec; 135(6):3887-96. PubMed ID: 2999233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus infection abrogates the stimulatory capacity of B cells to a major histocompatibility complex class-II-restricted proliferative T-cell clone.
    van Lochem EG; Bakker A; Snijder S; Aarts M; de Gast GC; Goulmy E
    Hum Immunol; 1995 Feb; 42(2):137-44. PubMed ID: 7744617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
    J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Epstein-Barr virus-transformed, autologous B-lymphoblastoid cells as antigen-presenting cells for establishment and maintenance of dengue virus-specific, human cytotoxic T lymphocyte clones.
    Livingston PG; Kurane I; Ennis FA
    J Virol Methods; 1997 Aug; 67(1):77-84. PubMed ID: 9274820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell responses to minor histocompatibility antigens.
    Lai PK; Waterfield JD; Gascoigne NR; Sharrock CE; Mitchison NA
    Immunology; 1982 Oct; 47(2):371-81. PubMed ID: 6214502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of CD8+ T cells by allogeneic class II-deficient B-cell lines derived from patients with bare lymphocyte syndrome.
    Jin Z; Yang SY
    Tissue Antigens; 1990 Mar; 35(3):136-43. PubMed ID: 2142838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
    Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative T cell clones directed at a human minor antigen.
    Zier KS
    Exp Clin Immunogenet; 1985; 2(1):36-42. PubMed ID: 2978829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell subsets required for in vivo and in vitro responses to single and multiple minor histocompatibility antigens.
    Wettstein PJ; Korngold R
    Transplantation; 1992 Aug; 54(2):296-307. PubMed ID: 1353915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.